Home Our Team Faculty Richard B. Womer, MD Profile

Richard B. Womer, MD

Richard B. Womer, MD

Attending physician

Professor of Pediatrics, University of Pennsylvania School of Medicine

Contact Richard B. Womer, MD


  • Department: Pediatrics
  • Division: Oncology
  • Primary Address:
    Children's Hospital of Philadelphia
    3501 Civic Center Boulevard
    10th Floor
    Philadelphia, PA 19104
  • (215) 590-2229


    • Professor of Pediatrics at the Children's Hospital of Philadelphia (2006 – present)
    • Associate Professor of Pediatrics at the Children's Hospital of Philadelphia (1994 – 2006)
    • Assistant Professor of Pediatrics at the Children's Hospital of Philadelphia (1991 – 1994)
    • Assistant Professor of Pediatrics, University of Pennsylvania School of Medicine (1985 – 1991)


    • M.D., University of Rochester (1978)
    • B.A., Biology, University of Rochester (1974)

    Extended Bio

    I specialize in sarcomas, which are cancers of connective tissues (such as bones, muscles and tendons). I coordinate the evaluation of patients with sarcomas, supervise their chemotherapy and coordinate their treatment with surgeons, radiation oncologists and other specialists. I am the senior member of our sarcoma team, which has three physicians and a nurse practitioner.

    When dealing with complicated diseases like sarcomas, it is important to take the time to do things right. Treating sarcomas involves lots of scans, tests, medicines and consultations with other professionals -- and families can find the process confusing and overwhelming. Many sarcoma patients are teenagers who are just beginning to gain their freedom, only to lose a lot of it as they become cancer patients. That is why it is important that I understand the patient and family, and that they understand what we are doing and why. We work to make the patient and family active participants in treatment.

    I also specialize in medication and chemotherapy safety. Working closely with other physicians, nurses, pharmacists, computer specialists and others, I try to make the complex process of ordering and administering chemotherapy and other medicines as straightforward and safe as possible, both in the Cancer Center and in the hospital as a whole.

    My research involves the development of sarcoma studies through the Children's Oncology Group, the world's largest childhood cancer research organization. I also work with biology researchers who are trying to combine clinical and biologic data to understand and treat sarcomas better.

    At The Children's Hospital of Philadelphia, we are fortunate to have people who study every variety of pediatric cancer in depth. Whether it's sarcoma or another cancer, there is someone in our division who is an expert and focuses their research on it -- and who knows other experts around the world. We also have nurses, child life specialists, nutritionists, social workers, physical therapists and others who specialize in treating children with cancer. That is a huge advantage for patients and families, and helps make CHOP a wonderful place to work.


    • Hill-Kayser Christine, Tochner Zelig, Both Stefan, Lustig Robert, Reilly Anne, Balamuth Naomi, Womer Richard, Maris John, Grupp Stephen, Bagatell Rochelle. Proton versus photon radiation therapy for patients with high-risk neuroblastoma: The need for a customized approach. Pediatric Blood & Cancer. Vol 60(10) . 2013 Oct:1606-11.
    • Weiss Aaron R, Lyden Elizabeth R, Anderson James R, Hawkins Douglas S, Spunt Sheri L, Walterhouse David O, Wolden Suzanne L, Parham David M, Rodeberg David A, Kao Simon C, Womer Richard B. Histologic and Clinical Characteristics Can Guide Staging Evaluations for Children and Adolescents With Rhabdomyosarcoma: A Report From the Children's Oncology Group Soft Tissue Sarcoma Committee. Journal of Clinical Oncology. 2013 Aug.
    • Womer Richard B, West Daniel C, Krailo Mark D, Dickman Paul S, Pawel Bruce R, Grier Holcombe E, Marcus Karen, Sailer Scott, Healey John H, Dormans John P, Weiss Aaron R. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. Journal of Clinical Oncology. Vol 30(33) . 2012 Nov:4148-54.
    • Borinstein Scott C, Barkauskas Donald A, Krailo Mark, Scher Daniel, Scher Lauren, Schlottmann Silke, Kallakury Bhaskar, Dickman Paul S, Pawel Bruce R, West Daniel C, Womer Richard B, Toretsky Jeffrey A. Investigation of the insulin-like growth factor-1 signaling pathway in localized Ewing sarcoma: a report from the Children's Oncology Group. Cancer. Vol 117(21) . 2011 Nov:4966-76.
    • Cooper Aaron, van Doorninck John, Ji Lingyun, Russell Darren, Ladanyi Marc, Shimada Hiroyuki, Krailo Mark, Womer Richard B, Hsu Jessie Hao-ru, Thomas Dafydd, Triche Timothy J, Sposto Richard, Lawlor Elizabeth R. Ewing tumors that do not overexpress BMI-1 are a distinct molecular subclass with variant biology: a report from the Children's Oncology Group. Clinical Cancer Research. Vol 17(1) . 2011 Jan:56-66.
    • van Doorninck John A, Ji Lingyun, Schaub Betty, Shimada Hiroyuki, Wing Michele R, Krailo Mark D, Lessnick Stephen L, Marina Neyssa, Triche Timothy J, Sposto Richard, Womer Richard B, Lawlor Elizabeth R. Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. Journal of Clinical Oncology. Vol 28(12) . 2010 Apr:1989-94.
    • Chou Alexander J, Kleinerman Eugenie S, Krailo Mark D, Chen Zhengjia, Betcher Donna L, Healey John H, Conrad Ernest U, Nieder Michael L, Weiner Michael A, Wells Robert J, Womer Richard B, Meyers Paul A,. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.. Cancer. Vol 115(22) . 2009 Nov:5339-48.
    • Imran Hamayun, Enders Felicity, Krailo Mark, Sim Franklin, Okuno Scott, Hawkins Douglas, Neglia Joseph, Randall R Lor, Womer Richard, Mascarenhas Leo, Arndt Carola A S. Effect of time to resumption of chemotherapy after definitive surgery on prognosis for non-metastatic osteosarcoma.. The Journal of bone and joint surgery. American volume. Vol 91(3) . 2009 Mar:604-12.
    • Granowetter L, Womer RB, Devidas M, Krailo MD, Wang C, Bernstein ML, Marina N, Leavey PJ, Gebhardt M, Healey JH, Shamberger RC, Goorin AM, Miser J, Meyer J, Arndt CAS, Sailer S, Marcus KJ, Perlman EJ, Dickman PS, Grier HE. Comparison of dose intensified versus standard chemotherapy for non-metastatic Ewing sarcoma family of tumors (ESFT): a Children’s Oncology Group Study Report. Journal of Clinical Oncology. Vol 27. 2009:2536-2541.